<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03978546</url>
  </required_header>
  <id_info>
    <org_study_id>250459</org_study_id>
    <nct_id>NCT03978546</nct_id>
  </id_info>
  <brief_title>Diagnostic Performance of Smart Supra Perimetry (The DPSSP Study)</brief_title>
  <acronym>DPSSP</acronym>
  <official_title>Diagnostic Performance of Smart Supra Perimetry (SSP) in Comparison With Standard Automated Perimetry (SAP) and Ocular Coherence Tomography (OCT).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Manchester University NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Manchester</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Manchester University NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Early glaucomatous visual field changes can be missed with the routinely used Standard
      Automated Perimetry (SAP) and the 24-2 test pattern due to limited sampling of the central 10
      degrees. While this shortcoming can be overcome with the addition of a 10-2 test, performing
      both tests places extra demand on the perimetric services (doubling test times) and patients.

      Smart Supra Perimetry (SSP) uses a new faster algorithm that can complete both 24-2 and 10-2
      test patterns in a similar time frame to a single 24-2 SAP test. This comparative study aims
      to determine the sensitivity and specificity (i.e. diagnostic accuracy) of SSP in identifying
      early glaucomatous visual field loss. A sample of 100 patients with early/suspect glaucoma
      will undergo SAP 24-2 and 10-2 (SITA algorithm) using Humphrey visual field perimetry and SSP
      24+10-2 using Henson 9000. Eyes will be categorised into 2 groups i.e., glaucoma and
      non-glaucoma, on the basis of structural changes to the disc as evaluated by the clinician.
      The sensitivity and specificity of the SAP and SSP tests will be established along with test
      duration. The size and location of defects established with both the SAP and SSP strategies
      will also be compared.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 20, 2019</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <intervention_model_description>All participants will have the same examinations but in a randomised order, these examinations are: Humphrey Visual Fields Test (10-2 and 24-2, SITA Standard), OCT Scan (Cube scan, Wide angle and macula scan) and Smart Perimetry - Henson 9000.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic performance of smart supra perimetry</measure>
    <time_frame>12 months</time_frame>
    <description>Area under the curve for Smart Suprathrold Perimetry using probability thresholds to differentiate early glaucoma from non-glaucomatous visual fields.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Diagnostic performance of Optical Coherent Tomography</measure>
    <time_frame>12 months</time_frame>
    <description>Sensitivity and specificity for Optical Coherent Tomography in the detection of early glaucoma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diagnostic performance of Standard Automated perimetry</measure>
    <time_frame>12 months</time_frame>
    <description>Sensitivity and specificity for Standard Automated perimetry in the detection of early glaucoma.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Glaucoma, Suspect</condition>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>Non-Glaucoma Patient Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants will complete the same assessments</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glaucoma Patient Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants will complete the same assessments</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Humphrey Visual Field Test</intervention_name>
    <description>SITA Standard and 24-2 and 10-2 visual field tests</description>
    <arm_group_label>Glaucoma Patient Arm</arm_group_label>
    <arm_group_label>Non-Glaucoma Patient Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Optical Coherence Tomography (OCT) Scan</intervention_name>
    <description>Circle and Wide Angle Scans</description>
    <arm_group_label>Glaucoma Patient Arm</arm_group_label>
    <arm_group_label>Non-Glaucoma Patient Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Smart Perimetry - Henson 9000</intervention_name>
    <description>24+10-2 Smart Supra test</description>
    <arm_group_label>Glaucoma Patient Arm</arm_group_label>
    <arm_group_label>Non-Glaucoma Patient Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Reliable SAP visual field results (fixation loss &lt; 33%, false positive &lt; 15% and false
             negative &lt; 20%).

          -  Visual acuity better or equal to 0.20 logMAR.

          -  Spherical refractive error within -6.00 to +6.00D and cylindrical error &lt;2.00D

          -  No ocular co-morbidity likely to affect the visual field or OCT results.

          -  Age: 40-80 yrs

        Additional inclusion criteria for glaucomatous group:

          -  Optic disc showing glaucomatous changes.

          -  SAP MD not worse than -6dB

        Additional inclusion criteria non-glaucoma group:

          -  Normal SAP visual field data (MD, PSD, GHT within normal range)

          -  No evidence of glaucoma or other Ocular co-morbidity in the eye suitable for the
             study.

        Exclusion Criteria:

        Exclusion criteria glaucomatous and control groups:

        â€¢ Anomalous discs, Tilted discs, myopic discs.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Charlene A Hyde</last_name>
    <phone>0161 701 0848</phone>
    <email>charlene.hyde@mft.nhs.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Monika Cien</last_name>
    <phone>0161 701 1765</phone>
    <email>monika.cien@mft.nhs.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Manchester Royal Eye Hospital</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charlene A Hyde</last_name>
      <phone>0161 701 0848</phone>
      <email>charlene.hyde@mft.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Subash Sukumar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>May 16, 2019</study_first_submitted>
  <study_first_submitted_qc>June 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2019</study_first_posted>
  <last_update_submitted>March 16, 2020</last_update_submitted>
  <last_update_submitted_qc>March 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>glaucoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

